top of page

Departures Capital: One Unique AI-Powered Biotech Stock To Watch Now? Rakovina Therapeutics Interview (TSXV:RKV)



Rakovina Therapeutics Inc. is focused on the development of new cancer treatments based on novel DNA-damage response technologies. The Company has established a pipeline of novel DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials and obtaining marketing approval for new cancer therapeutics from Health Canada, the United States Food and Drug Administration and similar international regulatory agencies.


Further information may be found at www.rakovinatherapeutics.com.

Recent Posts

See All

Comments


© 2023 Frontier Merchant Capital Group. All Rights Reserved.

  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
bottom of page